[Personalized treatment of Parkinson's disease].
Over the last two decades important achievements in research of Parkinson's disease led to the identification of specific pathways as well as histopathological fingerprints underlying the pathophysiology of the disease. This knowledge represents the basis for targeted disease-modifying treatment strategies. These treatment options target specific molecular defects in the causal chain or focus on the pathological α‑synuclein species and their propagation. This article highlights the most relevant treatment approaches that are currently being addressed in preliminary clinical trials.